Investor presentation

October 2026



VERICI Dx

TRANSPLANT DIAGNOSTICS

LSE: AIM | VRCI

A commercially validated platform • a rapidly expanding clinical footprint • a clear path to strategic value

Disclaimer

THIS PRESENTATION AND ITS CONTENTS ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA (THE "U.S.") (EXCEPT TO CERTAIN INVITED QIBS AND AIS (AS DEFINED BELOW), CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This document is the sole responsibility of the directors of Verici Dx plc (the "**Company**"). This document comprises an institutional marketing presentation. No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company, Singer Capital Markets Advisory LLP (the Company's nominated advisers) ("SCM Advisory"), Singer Capital Markets Securities Limited ("Singer Capital Markets") and Oberon Investments Limited ("Oberon") (the Company's joint brokers) or any of their respective directors, officers, partners, employees, agents or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any of them for any such information or opinions.

The information contained in, and communicated to you during, this presentation does not constitute, or form part of, any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for any shares in the Company nor shall this presentation, or any part of it, or the fact of its distribution, form the basis of, or be relied on, in connection with any contract. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company or for any investment decision taken in relation to its ordinary shares. In furnishing this presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation which may become apparent. This presentation is being supplied to you solely for your information and may not be copied, reproduced, further distributed to any person or published, in whole or in part, for any purpose No reliance may be placed for any purpose whatsoever on the information contained in this presentation or on the completeness, accuracy or fairness thereof. No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company, Singer Capital Markets, SCM Advisory or Oberon or any of their respective directors, officers, partners, employees, agents or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this document and no responsibility or liability is accepted by any of them for any such information or opinions. Notwithstanding the aforesaid, nothing in this paragraph shall exclude liability for any undertaking, representation, warranty or other assurance made fraudulently.


The distribution of this document or any copy of it in certain jurisdictions may be restricted by law and such distribution could result in violation of the laws of such jurisdictions. In particular, there are restrictions on the distribution of this document in the U.S., Australia, Canada, Japan, the Republic of South Africa, and New Zealand. Persons into whose possession this document comes are required to inform themselves about, and to observe, any restrictions and legal requirements in relation to the distribution of this document. Subject to certain limited exceptions, neither this presentation nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into the U.S., its territories or possessions.

This presentation is not an offer of securities for sale in the U.S. or to any U.S. person (within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), except to persons that are (i) "qualified institutional buyers" ("QIBs"), as defined in Rule 144A under the U.S. Securities Act, or (ii) "accredited investors" ("Als") as defined in Rule 501(a) of Regulation D under the U.S. Securities Act, or (iii) non-U.S. persons outside the U.S., in compliance with Regulation S under the U.S. Securities Act. By attending this presentation or by reading the presentation slides, you warrant and acknowledge that you fall within one of the categories (i), (ii) and (iii) above. Any failure to comply with the foregoing restrictions may constitute a violation of U.S. securities laws. There will be no public offer of any securities of the Company, including, but not limited to, the ordinary shares, in the U.S. or any other jurisdiction. No securities of the Company (including, but not limited to, the ordinary shares) have been, nor will they be, registered under the U.S. Securities Act or under any securities laws of any state of the U.S. and such securities may not be offered or sold in or into the U.S. except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. The Company does not intend to conduct a public offering of any of its securities (including, but not limited to, the ordinary shares) in the U.S. or in any other jurisdiction.

This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the prospects, developments and business strategies of the Company. Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises or if underlying assumptions prove incorrect, the Company's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Presentation and the Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

Kidney Transplant is a balancing act. Tutivia is the precision answer

- Doctors must balance rejection with the significant harms of immunosuppression. Tutivia is the test that gives doctors the ability to know how much drug to apply.
- Doctors are expected to order up to 12 tests per patient to understand this balance.
- Tutivia is Medicare reimbursed at $2,650



Why Tutivia can win. The only test that provides an accurate signal on accuracy for immunosuppression.

Tutivia
Next generation biomarkers

- Early, precise and actionable prognostic
- Highly specific
- Tutivia's RNA signature can be used by all patient sub-populations
- Able to assist doctors in the immunosuppression balancing

Cell-free (Cf)DNA providers
CareDx, Natera, Eurofins, IMDx


- Later injury marker
- Non-specific injury alarm – too little too late
- Aids the clinician as a rule-out test
- Ideal for surveillance use in a low-risk patient population

Tutivia solves critical issues for doctors and their patients.

Early adoption is converting into repeat usage

Product launched

- First full year of revenue $2.9m (FY25)
- Q3 YTD on track for 1,335 projected orders represented YoY growth of 52%
  - Growth from 2 established sales leads
- Full year on track to deliver 85% projected year-on-year growth on orders
  - Growth from 4 sales leads
  - Identified growth centers to take advantage of repeat ordering
  - Track record of Q4 growth
- 3 new centers already in high recurring orders



* Q1 2026

Foundations for growth in place


Current position

- Business development team covers 4 territories representing c. 65% of annual transplants
- More centres per territory than current headcount can address
- Unaddressed territories still need to be covered


Investment plan

- Break existing territories into sub-territories
- Short term hire additional sales personnel to continue growth
- Consider longer term strategic partnership for national reach


Ordering centres by State



Target territories – 4 addressed





Split of transplants by territory




Clear line of sight to profitability

- **Q1 FY26 growth** driven by
  - "Hunting": 6 new ordering centres
  - "Farming": >20% growth in 7 existing centres
- **Existing sales leads** have clear line-of-sight to significant growth in annual revenue.
- Each sales lead requires support from a team:
  - Medical Science Liaison
  - Field Support
  - Lab Tech, and
  - Customer Service
- **Breakeven** achieved at **c. 7,000 test** run rate (c. **1,750** tests per quarter)
- 2 New sales leads are being actively **recruited**







One platform. Multiple clinical decisions. Increasing strategic value

RNA sequencing and AI-enabled analytics underpin a growing kidney-transplant diagnostics portfolio.

LAUNCHED

TUTIVIA
LEAD PRODUCT · COMMERCIAL
Post-transplant
Medicare price of $2,650
Coverage determination from MolDx

PTRA
LICENSED TO THERMO FISHER
Pre-transplant risk assessment
Medicare price of $2,650

PIPELINE

PROTEGA
RUO[1] LAUNCH · FY26
Longer-term outcomes
Medicare price of $2,650

TRANSCRIPTX
LAUNCHING END OF FY26
Genetic testing in transplant –
Price range targeted $1,000-2,000 per test

URINE BASED DEVELOPMENT
Proteomic capability addressing clinical need for broader, kit-based screening

SPECIALITY TESTING SERVICES
Reflecting testing expertise in a growing niche of US healthcare in the Omics clinical space

2 layers of Intellectual Property

1 Research Use Only, full clinical launch is expected in due course within CLIA environment

Interim information - unaudited

- Revenues to 30 June $1.8m (H1 2025 Tutivia $1.1m). Ordered tests of 825, with 762 resulted tests giving an average reimbursement of c. $2,300 per test. Gross margin 72%.
- Cash at end of June, $2.4m, net proceeds from equity raise $3.0m.
  - Additional £8.75m equity raise post year end – management believes this will provide sufficient runway to achieve cash-flow breakeven by the end of 2027.
- Accounts Receivable of $2.1m (31 Dec 2025 - $1.5m)
  - Increase function of higher sales and time taken to get set up with commercial payors.
  - Commercial payors process is longer than forecasted but progressing and we don’t believe it to be bad debt.

High revenue growth. Breakeven within sight.

Verici has achieved significant development milestones and now is moving to scale its commercial success.

High Growth
52% YoY to date
80% expected YoY full year

~28,000*
US annual transplants TAM calculates as $900m

$2,650
Medicare Reimbursed ~70% of all transplant patients

US strategic partners
Reviewed

Gross Margin
72%

Coverage
National Medicare coverage determination with MOLDx with no exclusions

12x
Number of tests per patient

36 ordering centers
~20% penetration

23% patients
36 centers perform 23% of all transplants

* figure as of 2024

Key facts

- Tutivia: commercially available; Medicare price $2,650; national MolDx coverage determination.
- Tutivia US TAM cited at $900m; ~28,000 US kidney transplants annually; average 12 testing points per patient under current protocols.
- 36 ordering centres; these centres perform c.23% of US kidney transplants ($207m TAM).
- FY25 revenue $2.9m; FY26 85% projected YOY target increase in orders.
- Targeting revenue growth to be significant each year with the right resources.
- Sufficient runway to achieve cash-flow breakeven by the end of 2027.

Revenue growth reflects the compounding effect of repeat testing with clear line of sight to profitability

***IMPORTANT:** Forecasts, market sizes, valuation references and strategic-outcome statements are illustrative and should be independently verified.*